Entera Bio ENTX
NASDAQ ENTX
$3.03 +0.01 (+0.33%)
As of: Oct 21, 2026 · 11:41 AM EDT

Entera Bio (ENTX) Other Non-Current Liabilities (2025)

Updated

Entera Bio's Other Non-Current Liabilities was $393,000 in Q4 2025.

Analysis

Entera Bio (ENTX) Other Non-Current Liabilities (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn
10 Entera Bio 152.36 Mn 121.23 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 393,000.00
API Access

Entera Bio Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=ENTX&period=max&api_key=YOUR_API_KEY